Biocon Pharma Receives Key USFDA Approvals For Multiple Drugs

Biocon Pharma, a subsidiary of Biocon Limited, has received final approval from the US Food and Drug Administration (USFDA) for two important drug applications.

Drugs Details 

• Lenalidomide Capsules in 2.5 mg,5 mg,10 mg,15 mg,20 mg and 25 mg: Used for treating various types of blood cancers and anemia related to myelodysplastic syndromes (MDS).  

• Dasatinib Tablets in 20mg,50mg,70 mg, mg, 80 mg,100 mg,120 mg and 140 mg: A medication for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and acute lymphoblastic leukemia (Ph+ALL).  

Tentative Approval for Rivaroxaban Tablets

Along with the final approvals, Biocon Pharma has also secured tentative approval for Rivaroxaban Tablets USP in different strengths. This drug is used to treat deep vein thrombosis, pulmonary embolism and to reduce stroke risk in certain heart conditions.  

Strengthening the Drug Portfolio

These approvals contribute to Biocon’s growing portfolio of complex and high-value drug products, reinforcing its expertise in the pharmaceutical sector.  

Share Performance 

As of March 05, 2025, at 11:55 AM, the shares of Biocon Ltd are trading at ₹319.45 per share, reflecting a surge of 1.48% from the previous day’s closing price. Over the past month, the stock has registered a loss of 18.14%. The stock’s 52-week high stands at ₹404.70 per share, while its low is ₹244.55 per share.

Conclusion 

These approvals enhance Biocon Pharma’s footprint in the US market, expanding its portfolio of complex drugs for critical diseases. This milestone reinforces its commitment to delivering high-quality, affordable healthcare solutions globally.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.